Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §4

Epithalon — safety

Adverse events as reported, contraindications, warnings, and an explicit statement of what the safety evidence does not establish.

Document identifier
CEI-MN-039/4
Series
Compound monograph
Version
1.2
Published
26 May 2024
Last reviewed
26 Jan 2025
Next review
26 Jan 2027
Identifier
10.71829/cei.mono.39
Certainty
Very low
Cycle
2024 Q2

§4Safety

§4.1Adverse events reported in controlled trials

Table 4. Adverse events for Epithalon as reported in the trial safety tables the Institute holds. Percentages are of randomised participants in the stated trial and arm.

EventActive, %Comparator, %Difference, ppSource
No controlled safety datasetNone of adequate quality exists
Telomerase inductionIf the proposed telomerase mechanism operated as described, the implications for neoplasia would require careful study; none has been performed
A difference column is computed by the Institute from the two reported percentages and is not itself a published figure. Confidence intervals for adverse-event differences are not reported in the contributing trials and are not constructed here.

§4.2Contraindications

  • Not established — no marketing authorisation

§4.3Warnings and precautions

  • No independent replication of the central mechanistic claim
  • A telomerase-activating mechanism, if real, has unstudied neoplasia implications
  • No modern safety data

§4.4What this section does not establish

Related assessments: tolerability of incretin receptor agonists · acute pancreatitis · the rodent thyroid C-cell signal.[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS. Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory biomarkers of ageing. Advances in Gerontology 2020;10(1):1–8. doi:10.1134/S2079057020010063
  2. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.